- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05160467
Bio Electrical Impedance Analysis to Monitor Fluid Status During Deresuscitation Strategy in Continuous Renal Replacement Therapy (UF BIA)
Bio Electrical Impedance Analysis to Monitor Fluid Status During Deresuscitation Strategy in Continuous Renal Replacement Therapy: a Proof of Concept Study
Fluid overload is a poor prognostic factor in patients undergoing continuous renal replacement therapy in critical care. A strategy of active fluid removal by net ultrafiltration (UFnet) is one of the means to correct it. However, fluid overload is difficult to quantify: weight variations or cumulative fluid balance are easy to use but imprecise and not concordant markers, while reference methods such as isotope dilution are not adapted to daily practice.
Bio electrical impedance analysis (BIA) is used to estimate body composition, including hydration. It is a non-invasive, rapid and painless measurement. It is commonly used in chronic intermittent haemodialysis to estimate dry weight and guide fluid removal, with a demonstrated impact on blood pressure control. This analysis is feasible in the ICU. Fluid overload as defined by BIA correlates with mortality, most notably in acute renal failure and during continuous renal replacement therapy.
We routinely perform multifrequency segmental BIA (InBody S10, Seoul, Korea) in patients with fluid overload in our intensive care department. Since February 2021, we have implemented a protocol to systematically correct fluid overload by inducing negative fluid balance with UFnet in a manner appropriate to tissue perfusion. In this context, we systematically perform a BIA analysis on the day of the beginning of the fluid balance negativation and then every 48 hours during the first five days.
We would like to evaluate the relevance of BIA monitoring in these patients by comparing it to other parameters of evaluation of the volume status usually used.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Martin RUSTE, Dr
- Phone Number: +33472118956
- Email: martin.ruste@chu-lyon.fr
Study Locations
-
-
-
Bron, France, 69500
- Recruiting
- Hôpital cardiologique Louis Pradel Groupe Hospitalier Est
-
Contact:
- Martin RUSTE, M.D Msc
- Phone Number: +33472118956
- Email: martin.ruste@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age higher than 18
- Protocol directed deresucitation strategy with net ultrafiltration during continuous renal replacement therapy
- Bioelectrical impedance analysis available for the day of the initiation of the deresuscitation strategy and at day 5" -> "At least two bioelectrical impedance analysis available during the first 5 days of the initiation of the deresuscitation strategy".
Exclusion Criteria:
- Left ventricular assist device
- Patient opposition to the use of his health data
- Invalid bioelectrical impedance analysis
- Advanced directives to withhold or withdraw life-sustaining treatment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Deresuscitation cohort
Patients with fluid overload (defined by a cumulative fluid balance > 5%), stable hemodynamic (defined by Norepinephrine equivalent < 0.5µg/kg/min and nor clinical nor biological sign of hypoperfusion) and continuous renal replacement therapy. All these patients benefit in our service from a protocol directed, perfusion based deresuscitation strategy with a 2mL/kg/h net ultra filtration to induce negative fluid balance and correct fluid overload. If hypoperfusion occurs, the net ultra filtration is stopped; if pulmonary oedema or right ventricular dysfunction occurs, the net ultra filtration is set to 3mL/kg/h. We carried out at day 0, 1,3 and 5 bio electrical impedance analysis with an eight polar multifrequency bio impedance monitor (InBody S10), and monitor cumulative fluid balance with our prescription software and daily weight assessment. |
A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5. Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation coefficient between changes in extracellular water volume estimated by BIA and cumulative fluid balance between day 0 and day 5 (mL).
Time Frame: Coefficient correlation between the variation from day 0 to day 5 of extra cellular water and cumulative fluid balance
|
The extra cellular water is a volumetric value, given automatically by the InBody S10 device. The cumulative fluid balance at day 5 is the sum of the daily fluid balances between day 0 and day 5. Definition of the fluid balance = inputs - outputs :
|
Coefficient correlation between the variation from day 0 to day 5 of extra cellular water and cumulative fluid balance
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 532
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluid Overload
-
Nordsjaellands HospitalRigshospitalet, Denmark; University of CopenhagenRecruitingFluid Therapy | Fluid Overload | Fluid AccumulationSpain, Denmark, India, United Kingdom, Finland, Iceland, Lithuania, New Zealand, Norway, Sweden, Switzerland
-
Jagiellonian UniversityCompletedFluid Overload | Fluid LossPoland
-
Uppsala UniversityCompletedFluid Therapy | Fluid Overload | Critical CareSweden
-
Nova Scotia Health AuthorityWithdrawnFluid OverloadCanada
-
All India Institute of Medical Sciences, RishikeshCompleted
-
Medical University of ViennaCompleted
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompleted
-
University of JordanCompleted
-
Nuwellis, Inc.AKI Critical Care Research FoundationTerminatedFluid OverloadUnited States
Clinical Trials on Segmental multi-frequency bio electrical impedance analysis
-
Universitair Ziekenhuis BrusselCompletedIrritable Bowel SyndromeBelgium
-
Indonesia UniversityCompletedCritically IllIndonesia
-
Abant Izzet Baysal UniversityThe Scientific and Technological Research Council of TurkeyWithdrawnBreast Cancer | LymphedemaTurkey
-
Chang Gung Memorial HospitalCompleted
-
Assiut UniversityNot yet recruitingMetabolic Disorders in Children
-
Riphah International UniversityCompletedSubacute StrokePakistan
-
Sun Yat-sen UniversityCompletedEnd Stage Renal DiseaseChina
-
Universitair Ziekenhuis BrusselBaxter Healthcare CorporationRecruitingChronic Kidney Diseases | Protein Energy WastingBelgium
-
Kasr El Aini HospitalCompletedSarcopenia | End-stage Renal Disease | End-stage Kidney Disease | Dialysis Dependent Chronic Kidney DiseaseEgypt
-
NICHD Neonatal Research NetworkCompletedSepsis | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, NewbornUnited States